The #1 NYSE biotech company to watch as it transforms mental healthcare.

The psychedelics drugs market is anticipated to generate billions of dollars in the coming years and this company looks well positioned to... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe A Message from Stocks.News As the pharma industry gets closer and closer to delivering psychedelic substances that could have robust commercial use, it could catapult this company into the spotlight. Wall Street is betting tens of millions of dollars on psychedelic drugs that backers say could treat mental illness for a fraction of what it costs to do therapy with better-known treatments. Opportunities for psychedelics have been ignored since the 1960s but are now becoming mainstream again. One under-followed NYSE-traded company has an answer to the mental healthcare crisis and has a price target of $10.00 from H.C. Wainright! The company’s CYB003 and CYB004 could play a major role in helping to treat mental health conditions! The company believes that it is moving ever closer to the goal of developing treatment options, as demonstrated in the company’s Phase 1 and Phase 2 studies to date. The opportunity is ripe as the alternative drug market is estimated to reach nearly $16B this year! This company is changing the landscape of mental health care treatment with a game-changing small molecule called CYB-003. CYB-003 is being commercialized with a leading Phase II program in Major Depressive Disorder (MDD). MDD is a tremendous market, affecting over 17 million US adults. Antidepressants are the current treatment of choice, but their use has steadily increased over the past decade. Breakthrough data of CYB003 shows a rapid reduction in symptoms after ONE SINGLE DOSE! The results show significantly larger effects than comparators like SSRIs and Spravato, a notable prescription medicine, used along with an antidepressant, taken by mouth to treat: Adults with treatment-resistant depression. The revenue for them is highly anticipated drug candidate is expected to generate hundreds of millions of dollars. As this company prepares for data submission to the FDA for pivotal studies, learn why this is a critical time to have the company on your radar!

This message is a paid advertisement sent on behalf of Stocks.News, a third-party advertiser of MarketBeat. Why did I receive this email?     This message is a paid advertisement for Cybin Inc. (NYSE: CYBN) from Stocks.News and Sideways Frequency. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $15,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Stocks.News or Sideways Frequency. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Cybin Inc. (NYSE: CYBN) on Sideways Frequency' website for additional information about the relationship between Sideways Frequency and Cybin Inc. (NYSE: CYBN).     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: Top Analyst Exposes Imminent Crisis Hurtling Towards America